Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 14 at 2:00 PM EDT

Register Free →

Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed)

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institutes of Health, through the NIDDK and NHLBI, is issuing a single source competition for a cooperative agreement to support the Resource Center for the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D). This initiative aims to advance the understanding of cardiovascular disease in type 1 diabetes by collecting, analyzing, and sharing cardiovascular tissue from organ donors with type 1 diabetes, type 2 diabetes, and those without diabetes. The Resource Center is responsible for expanding the biorepository by collecting approximately 30 cases per year, performing extensive tissue characterization including microCT imaging and RNA quality assessments, and maintaining a data commons in collaboration with the NHLBI BioData Catalyst. Additionally, the center coordinates consortium activities and manages the distribution of biosamples to approved investigators. The funding opportunity, identified as RFA-DK-27-109, allows for a maximum project period of five years with annual direct cost limits of 1.5 million dollars. Applications are evaluated based on scientific and technical merit through the NIH peer review system, focusing on significance, investigator qualifications, and innovation. Eligible organizations must maintain active registrations in the System for Award Management and eRA Commons. The agreement is governed by 42 CFR Part 52 and 2 CFR Part 200, requiring strict adherence to data sharing policies, cybersecurity incident reporting within 48 hours of discovery, and the establishment of inter-member agreements regarding intellectual property and biospecimen sharing.

General Info

NIH funding for CaRe-T1D to collect and analyze cardiovascular tissue for diabetes research.

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUSA

Full Description

Show more

The NIDDK and NHLBI seek to advance their mission by a continuation of the Cardiovascular Repository for Type 1 Diabetes (CARE-T1D) consortium. The CARE-T1D biorepository was established in 2020 through RFA-DK-21-010 and has successfully collected, stored and analyzed cardiovascular tissue (hearts, aortas, carotid arteries and kidneys) from organ donors with type 1 diabetes, type 2 diabetes and without diabetes. A consortium was formed in 2024 through RFA-DK-23-021 to carry out research focused on hypothesis driven research on pathogenesis of cardiac disease in T1D using multi-omics and molecular approaches using the CARE-T1D resources. The goal of this funding opportunity is to continue the CARE-T1D resource center and its work in collecting, analyzing and sharing cardiovascular tissue from organ donors with type 1 diabetes, type 2 diabetes and without diabetes; maintaining and expanding the data repository with results from the consortium resources; and coordinating consortium activities.  This research seeks to improve our understanding of cardiovascular disease in type 1 diabetes and the differences with type 2 diabetes and no diabetes to develop therapies to treat this major cause of mortality for people with type 1 diabetes. 

This is a Forecast for a Single Source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract
Solicitation # HT942626RE002
The Defense Health Agency Contracting Activity is issuing a pre-solicitation notice for an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity (IDIQ) contract vehicle. This initiative aims to expand the pool of eligible contractors providing military medical research and development services, including laboratory and technical support, regulatory process expertise, and translational science services. The eventual Request for Proposal will be set aside exclusively for small businesses certified under the Small Business Administration 8(a) Program. Due to the need to implement recent FAR Overhaul guidance, the anticipated posting timeframe for the solicitation has been extended to late September 2026. The OMNIBUS IV vehicle operates with a base ordering period from June 20, 2022, through June 19, 2027, and an option ordering period extending to June 19, 2032. It features a cumulative ceiling of 10 billion dollars, with over 630 million dollars already awarded across 55 task orders to various end users, including the Naval Supply Systems Command and the Uniformed Services University of the Health Sciences. New awards from this on-ramp will align with the existing unrestricted vehicle. Prospective offerors must be registered in SAM.gov and will be required to submit proposals through the Procurement Integrated Enterprise Environment solicitation module once the formal RFP is released.
Defense Health Agency

POSTED

3 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Grant
Centers for Structural Biology of HIV and Other Infectious Diseases (U54 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-031
The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications for the Centers for Structural Biology of HIV and Other Infectious Diseases (RFA-AI-28-031). This funding opportunity seeks to establish multidisciplinary consortia of structural biologists and microbiologists to solve complex biological structures necessary for the prevention, treatment, and cure of HIV and other infectious diseases. The program emphasizes the use of advanced experimental approaches, including hybrid imaging, artificial intelligence, protein design, and dynamic computational modeling. NIAID intends to commit 33 million dollars in FY 2028, with individual application budgets not expected to exceed 3.5 million dollars in direct costs. The program is structured around a cooperative agreement requiring several functional components: an Administrative Core, a Workforce Development Core, two to four Scientific Cores, and three Research Projects. A Service and Resource Core is required for Infectious Disease Centers but prohibited for HIV Centers. Applications will be evaluated based on scientific and technical merit, relevance to program priorities, and the availability of funds, with a specific focus on multidisciplinary integration and innovation. Clinical trials are not allowed under this notice. Applicants must maintain active registrations in the System for Award Management and eRA Commons, and all Principal Investigators must have a linked ORCID ID. Required documentation includes a Data Management and Sharing Plan, a Resource Sharing Plan, and letters of institutional support. Strict cybersecurity requirements are in place, including multifactor authentication and a 48-hour incident notification window. The response deadline for this solicitation is May 28, 2027.
National Institutes Of Health

POSTED

4 days ago

DEADLINE

in 8 months
View Details
NAICS: 541714
New
Federal
Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories
Solicitation # 75N98026R00175
The National Institutes of Health is issuing a Sources Sought Notice to identify qualified research and development firms, small businesses, and subcontractors capable of providing biobanking, laboratory analytics, and informatics services for NIH biorepositories starting in fiscal year 2028. The primary objective is to support the operation and potential consolidation of repositories, specifically including the NIDA Center for Genetic Studies and the NIH Brain Development Cohorts Biobank. This is a market research effort to determine the availability of technically capable sources and to inform the government's decision on the appropriate acquisition method and potential small business set-asides. The required scope of work involves the secure storage and tracking of at least 3.5 million biospecimens, comprehensive data curation and management using auditable LIMS, and advanced laboratory capabilities such as high-throughput sequencing and CRISPR/Cas9 gene editing. Additionally, the contractor must provide informatics support to develop and maintain web portals, APIs, and secure cyberinfrastructure compliant with FISMA standards. Interested parties must submit a detailed capability statement, including experience, personnel qualifications, and facility descriptions, to the designated contract specialists by October 20, 2026.
National Institutes Of Health Nida

POSTED

4 days ago

DEADLINE

in 15 days
View Details
NAICS: 541714
New
Federal
Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Solicitation # ARPA-H-SOL-26-164
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

5 days ago

DEADLINE

in about 2 months
View Details
NAICS: 541714
New
Federal
SURPASS Webinar and Proposers' Day Information
Solicitation # ARPA-H-SN-26-164
The Advanced Research Projects Agency for Health (ARPA-H), under the Department of Health and Human Services, has issued Special Notice ARPA-H-SN-26-164 regarding the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program. This initiative aims to modernize clinical research by transforming drug and biologics development into a continuous learning system, with the goal of reducing development timelines from over ten years to fewer than four. The program focuses on creating disease-specific multi-arm platforms that integrate AI-powered operational infrastructure, in silico modeling, and advanced adaptive designs to enable a seamless transition from first-in-patient evaluation to confirmatory assessment. Key outputs include a reusable blueprint for future trials, simulation-based design tools, and continuous inference and adaptation approaches, all aligning with the goals of HHS Operation TrialBlazer. This specific notice serves as an informational announcement and does not constitute a formal solicitation for proposals. It invites interested parties to an informational webinar on October 15, 2026, and a two-day Proposers Day on November 6 and 9, 2026. Potential participants may optionally submit teaming profiles, lightning talk slides, and posters to showcase their expertise. Full program details and formal solicitation requirements are located under solicitation ARPA-H-SOL-26-164. All inquiries are directed to the SURPASS team, with Daria Fedyukina serving as the Technical Point of Contact.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

5 days ago

DEADLINE

in 7 days
View Details
NAICS: 541714
Federal
ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening
Solicitation # ARPA-H-SOL-26-165
The Advanced Research Projects Agency for Health (ARPA-H) is seeking proposals under solicitation ARPA-H-SOL-26-165 for the Comprehensive Organ System Modeling in Outer Space (COSMOS) initiative. This program aims to determine if microgravity in Low Earth Orbit (LEO) accelerates tissue aging across brain, cardiac, uterine, and kidney tissues compared to terrestrial rates. If the Tissue Aging Rate in Space (TARIS) is found to significantly exceed the Tissue Aging Rate on Earth (TAROE), the initiative intends to establish a high-throughput, autonomous drug screening platform in LEO to make biomedical research and development more cost-effective and faster than Earth-based methods. The project is structured into two sequential phases: a 27-month Phase I focused on establishing and validating microphysiological systems (MPS) to quantify aging rates, and a 15-month Phase II dedicated to developing age-related pathology models for pro-regenerative drug testing. Key requirements include the use of MPS or organoids for at least 75 percent of experimental samples, the creation of LEO twin experiments, and the establishment of a contractual partnership with at least one Fortune 100 biopharmaceutical company. The program schedule spans FY27 through FY30 and includes two planned space launches in months 39 and 41. Awards will be granted via multiple Other Transaction (OT) Agreements to the most advantageous proposers, including universities, non-profits, and businesses. Evaluation is based primarily on the innovation and feasibility of the technical approach, the potential to transform biomedicine, and the team's expertise in managing costs and schedules. Proposers must adhere to strict administrative requirements, including the BIOSECURE Act, NIH Genomic Data Sharing policies, and specific research security and cybersecurity disclosures. Full proposals are due by October 7, 2026.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

10 days ago

DEADLINE

in 2 days
View Details
NAICS: 541714
Federal
ARPA-H Emerging Health Innovators (EHI) Initiative
Solicitation # ARPA-H-SOL-26-150
The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) Initiative, solicitation ARPA-H-SOL-26-150, is a mentorship and research program designed to identify and engage early-career investigators. The program seeks proposals for cutting-edge biomedical, health, and community-engaged research across 16 specific topic areas, ranging from AI in life sciences to brain stimulation. To be eligible, the Principal Investigator must be within eight years of completing their first terminal degree. The initiative utilizes a two-step submission process, beginning with a mandatory anonymized Solution Summary due October 30, 2026, followed by Full Proposals due February 10, 2027, for selected applicants. Awards are issued as Other Transaction (OT) agreements with a total potential value not to exceed 1,050,000 dollars over three years. This funding is structured as a two-year base period capped at 700,000 dollars and an optional third year capped at 350,000 dollars, with payments triggered by the completion of 12 discrete, measurable quarterly milestones. Performance is monitored through monthly virtual progress reviews and the submission of milestone reports, which are reviewed by the government within 14 calendar days. Evaluation is based on technical merit, innovativeness, feasibility, risk mitigation, and alignment with the ARPA-H mission. All performers must maintain active SAM.gov registration and adhere to strict national policy requirements regarding research security and conflicts of interest.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

10 days ago

DEADLINE

in 4 months
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

NAICS: 541715
Grant
Continuation of the Exceptional Longevity Data Management and Coordinating Center (EL DMCC) (U24 Clinical Trial Not Allowed)The National Institute on Aging intends to issue a single U24 cooperative agreement award to support the continued operation and expansion of the Exceptional Longevity Data Management and Coordinating Center. Serving as the central hub for human longevity translational research, the center integrates deeply phenotyped cohorts and multi-omics datasets to enable cross-cohort analyses and collaborative research. Key responsibilities include data harmonization, the implementation of common data standards, and the management of the ELITE Portal, which provides the research community with secure access to analytical tools and cloud-based computational workspaces. The upcoming funding opportunity will require the Coordinating Center to expand its capabilities in artificial intelligence, machine learning, and the integration of diverse datasets across different species. Future objectives include the development of curated target knowledgebases for therapeutic targets, the enhancement of portal interoperability according to FAIR data principles, and the strengthening of community engagement through specialized training and workshops. This notice serves as a forecast to allow potential applicants to establish collaborations before the official solicitation is released.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

12 days ago

DEADLINE

N/A
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS